Zobrazeno 1 - 10
of 520
pro vyhledávání: '"Alice T, Shaw"'
Autor:
Jaime L. Schneider, MD, PhD, Alona Muzikansky, MA, Jessica J. Lin, MD, Elizabeth A. Krueger, NP, Inga T. Lennes, MD, Joseph O. Jacobson, MD, Michael Cheng, MD, Rebecca S. Heist, MD, MPH, Zofia Piotrowska, MD, MHS, Justin F. Gainor, MD, Alice T. Shaw, MD, PhD, Ibiayi Dagogo-Jack, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 7, Pp 100347- (2022)
Introduction: The central nervous system (CNS) is a common site of progression among patients with ROS1-rearranged lung cancer receiving crizotinib. We conducted a phase 2 study to evaluate the intracranial efficacy of lorlatinib in patients with ROS
Externí odkaz:
https://doaj.org/article/93980cd67c144363bbe8189dbeede26f
Autor:
Stephen R. Fairclough, Lesli A. Kiedrowski, Jessica J. Lin, Ori Zelichov, Gabi Tarcic, Thomas E. Stinchcombe, Justin I. Odegaard, Richard B. Lanman, Alice T. Shaw, Rebecca J. Nagy
Publikováno v:
Experimental Hematology & Oncology, Vol 8, Iss 1, Pp 1-6 (2019)
Abstract Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L792 mutations, a non-covalent m
Externí odkaz:
https://doaj.org/article/a2642d01b2c14be0a9b216a7597b136a
Autor:
Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima, Yuki Shimizu, Yosuke Seto, Tomoko Oh-hara, Sumie Koike, Naoki Nakao, Hiroyuki Hanzawa, Kengo Watanabe, Satoshi Yoda, Noriko Yanagitani, Aaron N. Hata, Alice T. Shaw, Makoto Nishio, Naoya Fujita, Takeshi Isoyama
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
The treatment of ROS1-rearranged non-small cell lung cancer with the TKI crizotinib is limited due to the emergence of resistance. Here, the authors develop a new ROS1/NTRK inhibitor, DS-6051b, which overcomes crizotinib resistance in preclinical mod
Externí odkaz:
https://doaj.org/article/1fb146a2c258459e81f631757ffb5a98
Autor:
Arvind Ravi, Matthew D. Hellmann, Monica B. Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T. Griffin, Natalie I. Vokes, Mustafa Sakhi, Vashine Kamesan, Hira Rizvi, Biagio Ricciuti, Patrick M. Forde, Valsamo Anagnostou, Jonathan W. Riess, Don L. Gibbons, Nathan A. Pennell, Vamsidhar Velcheti, Subba R. Digumarthy, Mari Mino-Kenudson, Andrea Califano, John V. Heymach, Roy S. Herbst, Julie R. Brahmer, Kurt A. Schalper, Victor E. Velculescu, Brian S. Henick, Naiyer Rizvi, Pasi A. Jänne, Mark M. Awad, Andrew Chow, Benjamin D. Greenbaum, Marta Luksza, Alice T. Shaw, Jedd Wolchok, Nir Hacohen, Gad Getz, Justin F. Gainor
Publikováno v:
Nature Genetics. 55:807-819
Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here the first jo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23c93237364619553aac7a7eb39f6ddf
https://doi.org/10.1038/s41588-023-01355-5
https://doi.org/10.1038/s41588-023-01355-5
Autor:
Benjamin J, Solomon, Todd M, Bauer, Tony S K, Mok, Geoffrey, Liu, Julien, Mazieres, Filippo, de Marinis, Yasushi, Goto, Dong-Wan, Kim, Yi-Long, Wu, Jacek, Jassem, Froylán López, López, Ross A, Soo, Alice T, Shaw, Anna, Polli, Rossella, Messina, Laura, Iadeluca, Francesca, Toffalorio, Enriqueta, Felip
Publikováno v:
The Lancet Respiratory Medicine. 11:354-366
After a median follow-up of 18·3 months, the third-generation anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor, lorlatinib, improved progression-free survival in patients with treatment-naive, ALK-positive non-small-cell lung cancer in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c30ab31bbb51ec67da568ccb47968f7
https://doi.org/10.1016/s2213-2600(22)00437-4
https://doi.org/10.1016/s2213-2600(22)00437-4
Autor:
Sai-Hong Ignatius Ou, MD, PhD, Yutaka Fujiwara, MD, PhD, Alice T. Shaw, MD, PhD, Noboru Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Frank Fan, MD, Yuki Hao, MSc, Yanfei Gao, MSc, Pasi A. Jänne, MD, Takashi Seto, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100108- (2021)
Introduction: Taletrectinib (AB-106/DS-6051b) is an oral, potent selective ROS1 and pan-NTRK tyrosine kinase inhibitor (TKI). Preclinically, taletrectinib has activity against ROS1 G2032R solvent-front mutation. Methods: Patients with ROS1+ NSCLC enr
Externí odkaz:
https://doaj.org/article/64233781feae4b948e90754ce61ce9a4
Publikováno v:
Nature Cancer. 4:330-343
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c5af24de0cd26fac0617e42db4d41b1
https://doi.org/10.1038/s43018-023-00515-0
https://doi.org/10.1038/s43018-023-00515-0
Autor:
Justin F. Gainor, MD, Shirish Gadgeel, M.B.B.S., Sai-Hong I. Ou, MD, PhD, Beow Yeap, ScD, Gregory A. Otterson, MD, Alice T. Shaw, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100045- (2020)
Introduction: RET rearrangements define a distinct molecular subset of NSCLC. The multikinase inhibitor ponatinib reveals potent activity in preclinical models of RET-rearranged NSCLC. Methods: In this single-arm, multicenter, phase II trial, we eval
Externí odkaz:
https://doaj.org/article/53f5be82f7374af8a8b945fa60ca91a8
Autor:
David P. Kodack, Anna F. Farago, Anahita Dastur, Matthew A. Held, Leila Dardaei, Luc Friboulet, Friedrich von Flotow, Leah J. Damon, Dana Lee, Melissa Parks, Richard Dicecca, Max Greenberg, Krystina E. Kattermann, Amanda K. Riley, Florian J. Fintelmann, Coleen Rizzo, Zofia Piotrowska, Alice T. Shaw, Justin F. Gainor, Lecia V. Sequist, Matthew J. Niederst, Jeffrey A. Engelman, Cyril H. Benes
Publikováno v:
Cell Reports, Vol 21, Iss 11, Pp 3298-3309 (2017)
Personalized cancer therapy is based on a patient’s tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis. Here, we aim to develop an in vitro functional assay of a patient’s living cancer cells that could complemen
Externí odkaz:
https://doaj.org/article/016db17b42214179a6109aad4764e0a1
Autor:
Christopher Alvarez-Breckenridge, Julie J. Miller, Naema Nayyar, Corey M. Gill, Andrew Kaneb, Megan D’Andrea, Long P. Le, Jesse Lee, Ju Cheng, Zongli Zheng, William E. Butler, Pratik Multani, Edna Chow Maneval, Sun Ha Paek, Brian D. Toyota, Dora Dias-Santagata, Sandro Santagata, Javier Romero, Alice T. Shaw, Anna F. Farago, Stephen Yip, Daniel P. Cahill, Tracy T. Batchelor, A. John Iafrate, Priscilla K. Brastianos
Publikováno v:
npj Precision Oncology, Vol 1, Iss 1, Pp 1-5 (2017)
Abstract Glioneuronal tumors constitute a histologically diverse group of primary central nervous system neoplasms that are typically slow-growing and managed conservatively. Genetic alterations associated with glioneuronal tumors include BRAF mutati
Externí odkaz:
https://doaj.org/article/566d486d09384fbf8d3ccde6c3b6828b